학술논문
SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p245-245, 185p
Subject
Language
ISSN
0732183X